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Nowadays the most widely used antidepressants are selective serotonin reuptake inhibitors (SSRI) or
noradrenaline reuptake inhibitors (NRI), however, these take four to eight weeks to exert their effects
and each drug is efﬁcacious only in 60e70% of patients. In an attempt to improve the efﬁcacy of anti-
depressants, new drugs that also modify dopamine levels are being developed. The aim of this study was
to investigate the impact of L-DOPA administration on the effect elicited by antidepressants on seroto-
nergic and noradrenergic neurotransmission. To this end, single-unit extracellular recordings of the
noradrenergic nucleus, locus coeruleus (LC), and the serotonergic nucleus, dorsal raphe (DRN) combined
with behavioural approaches were performed. L-DOPA did not modify the basal neuronal activity in
either the LC or the DRN or induce any change in the modiﬁed forced swimming test. However, L-DOPA
enhanced the neuronal response to reboxetine in the LC and increased its antidepressant-like effects but
counteracted the effect of ﬂuoxetine on neurons in the LC and decreased its antidepressant-like effect.
The sensitivity of neurons in the DRN to reboxetine and ﬂuoxetine was not altered by the administration
of L-DOPA. Taken together, these results indicate that L-DOPA modiﬁes the effect of SSRI and NRI anti-
depressants in opposing ways.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Major depression is a recurrent or chronic mood disorder that
results in impaired psychosocial function. Patients who fail to reach
remission have an increased tendency to relapse. In industrialised
societies, depression affects approximately 15% of the general
population (Kessler et al., 2007). The most commonly used anti-
depressants are the selective serotonin reuptake inhibitors (SSRI)
followed by the noradrenaline reuptake inhibitors (NRI), which
modulate serotonergic and/or noradrenergic neurotransmission,
respectively. Both groups of drugs are similar in terms of onset of
antidepressant effect and efﬁcacy, taking four to eight weeks to
exert their antidepressant effect and being efﬁcacious in only 60e
70% of patients. Several efforts to increase the efﬁcacy have been
made using concomitantly an antidepressant with a substanceaperitoneal; i.v., intravenous;
uleus; mFST, modiﬁed forced
inhibitors; PD, Parkinson’s
þ34 94 6013220.
Y-NC-ND license.from another drug class, among others those that act on the
dopaminergic system (Bauer et al., 2010; Blier, 2008; Papakostas,
2006; Vieta and Colom, 2011).
The involvement of the dopaminergic system in the etiopa-
thology of depression is supported by several evidences. Lower
concentrations of homovanilic acid, a chief metabolite of dopamine,
have been reported in cerebrospinal ﬂuid, plasma, serum and urine
of depressed patients (Engstrom et al., 1999; Hamner and Diamond,
1996; Lambert et al., 2000). In addition, dopamine receptor and
transporter levels are decreased in depressed patients (Klimek
et al., 2002; Meyer et al., 2001), and pathologies that present low
concentrations of dopamine, such us Parkinson’s disease, have
a high prevalence of depressive episodes (Hemmerle et al., 2012;
Lieberman, 2006). Clinical studies have indicated that dopami-
nergic receptor agonists are effective in the treatment of otherwise
treatment-resistant depression patients (Cassano et al., 2005, 2004;
Dhillon et al., 2008; Inoue et al., 2010; Kapur and Mann, 1992;
Schulte-Herbruggen et al., 2012).
Previous studies have demonstrated that both SSRI and NRIs
inhibit neuronal activity in both the locus coeruleus (LC) and the
dorsal raphe nucleus (DRN) (Miguelez et al., 2009, 2011b). Inter-
estingly, depletion of dopamine concentrations altered neuronal
C. Miguelez et al. / Neuropharmacology 67 (2013) 349e358350sensitivity to those antidepressants. It was demonstrated that
when dopamine is absent, the SSRI, ﬂuoxetine, is less effective in
inhibiting noradrenergic neurons, whereas the NRI, reboxetine, is
more effectively inhibiting serotonergic neurons (Miguelez et al.,
2011b). SSRIs and NRIs are often co-administered with the dopa-
mine precursor L-3,4-dihydroxyphenylalanine (L-DOPA) since
parkinsonian patients frequently suffer depressive episodes.
L-DOPA is transformed into dopamine that as endogenous neuro-
transmitter can act on dopaminergic receptors. Alternatively, it can
also be converted into noradrenaline, bind with high afﬁnity
a2-adrenoceptors (Alachkar et al., 2010) or be stored by seroto-
nergic afferents (Arai et al., 1994, 1995; Mercuri and Bernardi,
2005). As L-DOPA can act via various mechanisms depending on
the neurotransmission system, it is likely that its administration
differently affects the antidepressant efﬁcacy of SSRI or NRI.
This study aims to investigate how L-DOPA inﬂuences the effect
of antidepressants. The elucidation of such interaction can help to
design new strategies for the treatment of depression, especially for
treatment-resistant cases or drug-naïve patients that require a fast
therapeutic answer. To accomplish this, both electrophysiological
and behavioural approaches were used. Our results show that
L-DOPA augments the effects of reboxetine but attenuates the
effects of ﬂuoxetine.
2. Materials and methods
2.1. Animals
Male Sprague-Dawley rats (weighing 250e400 g) were housed under
a 12:12 h light:dark cycle and given ad libitum access to food and water. Every
effort was made to minimise animal suffering and the number of animals used.
All experimental protocols were reviewed and approved by the Local Committee
for Animal Experimentation at the University of the Basque Country and the
University of Cadiz. All of the experiments were performed in compliance with the
European Community Council Directive on “The Protection of Animals Used for
Experimental and Other Scientiﬁc Purposes” (86/609/EEC) and with Spanish Law
(RD 1201/2005) for the care and use of laboratory animals. All rats were experi-
mentally naïve and were used only once. Behavioural tests were performed
between 9:00 and 14:00 h.
2.2. Electrophysiological procedures
Single-unit extracellular recordings of LC and DRN neurons were performed as
previously described (Miguelez et al., 2011b). The animals were anaesthetised with
chloral hydrate (400 mg/kg, intraperitoneally, i.p.). Each rat was placed in
a stereotaxic frame, and its body temperature was maintained at approximately
37 C for the entire experiment. To record from the LC, the rat’s head was oriented
at 15 to the horizontal plane (i.e., nose down). To record from the DRN, a ligature
was applied, and the sagittal sinus was subsequently cut. Then, a recording elec-
trode was lowered into the LC (relative to lambda: AP: 3.7 mm, ML: þ1.1 mm,
DV: 5.5 to 6.5 mm) or the DRN (relative to lambda: AP: þ1.0 mm, ML: 0 mm,
DV: 4.5 to 6.0 mm). Neurons in the LC were identiﬁed by the following criteria:
1) spontaneous activity with a regular rhythm and a ﬁring rate between 0.5 and
5 Hz; 2) characteristic spikes with a long-lasting, positiveenegative waveform; and
3) a biphasic excitationeinhibition response to pressure that was applied to the
contralateral hind paw (paw pinch). Burst-ﬁring onset and end were deﬁned as the
concurrence of two spikes with an interspike interval between 0.08 and 0.16 s,
respectively (Dawe et al., 2001). Serotonergic neurons in the DRN were identiﬁed
by the following criteria: 1) wide-duration action potentials that occur between
1e2 ms positiveenegative spikes; 2) a regular rhythm; and 3) a slow ﬁring rate
(0.5e3 Hz).
The ﬁring patterns were analysed ofﬂine with a script ﬁle using the computer
software Spike2, and the following parameters were calculated: the ﬁring rate, the
coefﬁcient of variation (the percentage ratio of standard deviation to the mean
interval value of an interspike time-interval histogram), the percentage of spikes in
burst and the percentage of cells that exhibited burst ﬁring and responded to
intravenous drug administration. Only one cell was studied per animal when any
drug was administered.
At the end of each experiment, Chicago Sky Blue 6B (SigmaeAldrich, Spain) was
used to mark the recording site while a 5 mA cathodic current was passed through
the recording electrode for 10 min. The animals were deeply anaesthetised and
transcardially perfused with 4% ice-cold paraformaldehyde that had been prepared
in 0.1 M phosphate buffer. The brains were removed and transferred to a 25%
sucrose solution until they sank. Coronal 40-mm sections were cut using a freezingmicrotome (HM 430, Microm International, Germany), mounted on gelatinised
glass and stained with neutral red. For all of the experiments that were included in
this study, the location of the recording sites was veriﬁed as being within the LC or
the DRN.
2.3. Modiﬁed forced swimming test
The modiﬁed forced swimming test (mFST) was used to determine the effect of
administering L-DOPA on the antidepressant-like effects of reboxetine and ﬂuox-
etine. This test is commonly used by numerous laboratories worldwide, being
considered the most widely used animal test predictive of antidepressant action
(Alba-Delgado et al., 2013; Bravo et al., 2012; Cryan et al., 2005). The mFST was
conducted as previously described (Detke et al., 1995). Each rat was individually
placed in a Pyrex cylinder (20  46 cm) that had been ﬁlled to a depth of 30 cm
with water at 23e25 C. The water was changed for each animal. After 15 min, the
rat was removed, dried and returned to its home cage. Twenty-four hours after its
ﬁrst exposure, the animal was again placed in the cylinder for 5 min and its
behaviour was monitored from above by a video camera. A highly trained observer
who was blind to the treatment subsequently evaluated the predominant
behaviour that occurred during each 5-s period of the 300-s test. The following
behaviours were measured: climbing behaviour, deﬁned as upward-directed
movements of the forepaws that usually occurred along the side of the swim
chamber; swimming behaviour, deﬁned as movement throughout the chamber
including crossing across quadrants of the cylinder; and immobility, characterised
by a lack of activity other than the amount required to keep the rat’s head above
the water. Drug injections were administered i.p. three times at 1 h, 5 h and 23.5 h
prior to the test session.
An increase in swimming behaviour has previously been observed in response
to antidepressants that enhance serotonergic neurotransmission (e.g., SSRIs),
whereas an increase in climbing behaviour has been observed in response to anti-
depressant drugs that selectively affect noradrenergic transmission (Detke et al.,
1995). A reduction in immobility during the mFST was considered to indicate
antidepressant-like activity.
2.4. Locomotor activity
To explore the possible inﬂuence of motor activity levels in the results of the
mFST, spontaneous locomotion was assessed in the rats. Similar to the protocol of
administration that was used in the mFST, naïve animals were injected three times
at 23.5 h, 5 h, and 1 h before the test. Locomotor activitywas assessed using an open-
ﬁeld (20  30  30 mm) bar system that was provided by LETICA Science Instru-
ments (LSI Letica, LE 886, Panlab S.L., Cornellá, Barcelona). The ﬂoor consisted of
a stainless steel grid that was constructed from 28 bars of 3 mm of diameter each
one; the bars were associated with a detector that sensed changes in electric
resistance. Each animal was placed in the chamber and allowed to explore freely. The
animal’s activity was monitored for 5 min, and data on horizontal activity were
collected.
2.5. Drugs
Chloral hydrate, reboxetine mesylate (Tocris), L-DOPA (L-3,4-
dihydroxyphenylalanine methyl ester hydrochloride), benserazide-HCl (Sigmae
Aldrich), and ﬂuoxetine hydrochloride (courtesy of FAES FARMA) were all used in
this study. Chloral hydrate, L-DOPA and benserazide were prepared in 0.9% saline;
ﬂuoxetine and reboxetine were prepared in distilled water.
2.6. Statistical analysis
The data were expressed as the mean values  S.E.M., and the level of signiﬁ-
cance was set at p < 0.05. For the electrophysiological data, all changes in the ﬁring
rate are expressed as percent change from the baseline ﬁring rate, which was
deﬁned as the mean ﬁring rate during the 3 min prior to drug injection. Any
response to the administration of drugs was evaluated according to dose-
concentrationeeffect curves that were non-linearly ﬁtted to a logistic three-
parameter equation as previously described (Miguelez et al., 2009, 2011b). The
effect of L-DOPA was assessed by using a paired Student’s t-test to compare all
electrophysiological parameters except for neurons with bursts and the frequency of
neuronal responses, which were analysed using a c2 test. For doseeeffect curves
with one or two independent variables, one-way or two-way ANOVAs were used,
respectively. Any ANOVA that showed signiﬁcance was followed by the Bonferroni
post hoc test. In the mFST and the locomotor activity test, the effects of L-DOPA,
reboxetine or ﬂuoxetine were compared to the saline group, and an unpaired
Student’s t-test was used to compare two groups; alternatively, a one-way ANOVA
followed by the Dunnett test was used. To study the interactions between drugs,
a statistical analysis was performed using a two-way ANOVA. The factors of variance
were L-DOPA treatment and reboxetine or ﬂuoxetine treatment. To study the effect
of co-administering L-DOPA and an antidepressant a one-way ANOVA was used
followed by the Dunnett test. For clarity, all two-way ANOVAs have been summar-
ised in Table 2.
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3.1. The administration of L-DOPA does not modify the basal
electrophysiological characteristics of noradrenergic neurons in the
locus coeruleus or serotonergic neurons in the dorsal raphe nucleus
To study the interaction between L-DOPA and antidepressants
we ﬁrst characterised the effect of a single dose of L-DOPA (6 mg/kg
plus 15 mg/kg of benserazide, i.p.) on the electrophysiological
parameters of neurons in the LC and the DRN. This dose was
selected since it has been proved to increase dopamine concen-
trations in intact rats (Lindgren et al., 2010). Recordings from 24
noradrenergic neurons in the LC and 17 serotonergic neurons in the
DRN were collected before and 5 min after the administration of L-
DOPA (one neuron per animal). All of the cells exhibited typical
electrophysiological characteristics of noradrenergic or seroto-
nergic neurons, as described above, and were localised within the
LC and the DRN, respectively.
In the LC, administering L-DOPA did not modify the ﬁring rate
(1.52 0.11 Hz vs.1.54 0.12 Hz, n¼ 24), the coefﬁcient of variation
(35  3% vs. 36  3%, n ¼ 22), the percentage of spikes in burst
(2.00  0.00% vs. 2.33  0.24%, n ¼ 9), the mean number ofFig. 1. The effect of reboxetine and ﬂuoxetine on noradrenergic neurons in the locus coeruleu
reboxetine (0.025e0.8 mg/kg, i.v.) on the ﬁring rate of noradrenergic neurons in the LC of con
same way, histograms representing the inhibitory effects of ﬂuoxetine (2.5e20 mg/kg, i.v.) on
(D) rats. The doseeresponse curves for reboxetine (C) and ﬂuoxetine (D) on noradrenergic n
before the antidepressant. The symbols represent the means  S.E.M. of the percentage of re
reboxetine control, the reboxetine þ L-DOPA, the ﬂuoxetine control and the ﬂuoxetine þ L-DO
group (two-way ANOVA followed by a Bonferroni post hoc test).spikes/burst (2.210.73 vs. 2.25 0.70, n¼ 9) or the percentage of
neurons with burst ﬁring (38% vs. 38%) before and after L-DOPA,
respectively. Similarly, in the DRN, administration of L-DOPA did not
change the neuronal ﬁring rate (1.71  0.14 Hz and 1.67  0.14 Hz,
n ¼ 17) or the coefﬁcient of variation (24  2% and 24  2%) before
and after L-DOPA, respectively. Additionally we studied the effect of
12mg/kg of L-DOPA in LC basal electrophysiological parameters and
LC and DRN neuron basal activity recorded 60 min after 6 mg/kg of
L-DOPA administration. No differences were observed in either
experiment (data not shown).
Overall, L-DOPA, at the selected dosage, did not alter any basal
electrophysiological parameters either in the LC or DRN.
3.2. The administration of L-DOPA enhances the effect of reboxetine
and attenuates the effect of ﬂuoxetine on noradrenergic neurons in
the locus coeruleus
As observed in previous studies (Miguelez et al., 2011b; Szabo
and Blier, 2001), the acute administration of reboxetine (0.025e
0.8 mg/kg, i.v.) in control rats signiﬁcantly decreased the sponta-
neous ﬁring activity of neurons in the LC in a dose-dependant
manner (Fig. 1A). When reboxetine treatment was preceded by thes of control and L-DOPA-pretreated rats. The histogram portrays the inhibitory effect of
trol (A) and L-DOPA-pretreated (6 mg/kg þ 15 mg/kg of benserazide, i.p.) (B) rats. In the
the ﬁring rate of noradrenergic neurons in the LC of control (C) and L-DOPA-pretreated
eurons in the LC of control and L-DOPA-injected rats. L-DOPA was administered 5 min
duction from the basal ﬁring rate, and n ¼ 8, 6, 15 and 13 animals were included in the
PA groups, respectively; ***: p < 0.001 and *: p < 0.05 when compared with the control
Table 1
A summary of two-way ANOVAs. The effect of antidepressants and L-DOPA on the ﬁring rate of neurons in the locus coeruleus and dorsal raphe nucleus, the modiﬁed forced
swimming test and the locomotor activity test. P values and F values result from one- or two-way ANOVAs. The factors are represented in columns.
Reboxetine L-DOPA Interaction Fluoxetine L-DOPA Interaction
Electrophysiology
Locus coeruleus F(4,49) ¼ 91.47*** F(1,49) ¼ 35.22*** F(4,49) ¼ 3.03* F(4,87) ¼ 33.36*** F(1,87) ¼ 22.14*** F(4,87) ¼ 1.013
Dorsal raphe F(6,67) ¼ 79.89*** F(1,67) ¼ 0.16 F(6,67) ¼ 1.08 F(6,92) ¼ 78.19*** F(1,92) ¼ 0.05 F(6,92) ¼ 0.45
Modiﬁed forced swimming test
Immobility F(3,116) ¼ 16.03*** F(2,116) ¼ 4.93** F(6,116) ¼ 1.05 F(1,52) ¼ 39.28*** F(2,52) ¼ 4.20* F(2,52) ¼ 3.55*
Swimming F(3,116) ¼ 6.50*** F(2,116) ¼ 2.85 F(6,116) ¼ 1.77 F(1,52) ¼ 75.96*** F(2,52) ¼ 0.84 F(2,52) ¼ 1.26
Climbing F(3,116) ¼ 22.37*** F(2,116) ¼ 6.50*** F(6,116) ¼ 1.91 F(1,52) ¼ 24.43*** F(2,52) ¼ 0.48 F(2,52) ¼ 1.40
Locomotor activity F(3,101) ¼ 19.39*** F(2,101) ¼ 26.23*** F(6,101) ¼ 0.68 F(1,52) ¼ 313.73*** F(2,52) ¼ 3.05 F(2,52) ¼ 0.80
*p < 0.05, **p < 0.01 and ***p < 0.001.
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dant inhibitory effect on neurons in the LC (F(4,23) ¼ 46.41,
p< 0.0001, one-way ANOVA) (Fig.1B). However, the administration
of L-DOPA signiﬁcantly shifted the doseeresponse curve of rebox-
etine to the left (Table 1 and Fig. 1E) and decreased the ED50 value
compared to the control group (ED50¼ 0.05  0.01 mg/kg, n ¼ 6 vs.
ED50 ¼ 0.11  0.02 mg/kg, n ¼ 5, for L-DOPA and control group,
respectively, p < 0.01, unpaired Student’s t-test).
The acute administration of ﬂuoxetine (2.5e20 mg/kg i.v.)
signiﬁcantly inhibited spontaneous ﬁring activity in the LC in
a dose-dependant manner, as already reported (Miguelez et al.,
2009) (Fig. 1C). When the administration of ﬂuoxetine was
preceded by the administration of L-DOPA, this inhibitory effect
was also observed (F(4,39) ¼ 10.69, p < 0.0001, one-way ANOVA)
(Fig. 1D); however, the effect of ﬂuoxetine was attenuated in this
case (Table 1 and Fig. 1F). The inhibition of neurons in the LC was
signiﬁcantly weaker when doses of 15 and 20 mg/kg of ﬂuoxetine
were given than in control rats (Bonferroni post hoc test,
p < 0.05). The percentage of neurons in the LC that responded to
ﬂuoxetine was similar between the groups (c2 ¼ 0.59, df ¼ 1,
p > 0.05) with 71% and 81% in the control and the L-DOPA group,
respectively.
In conclusion, the combination of L-DOPA with reboxetine or
ﬂuoxetine either augmented or attenuated the inhibitory effect of
the antidepressant on LC neurons, respectively.
3.3. The administration of L-DOPA does not change the effect of
either reboxetine or ﬂuoxetine on serotonergic neurons in the dorsal
raphe nucleus
The rats were injected with 6 mg/kg of L-DOPA (together
with 15 mg/kg of benserazide, i.p.) 5 min before reboxetine
(0.625e60 mg/kg, i.v.) or ﬂuoxetine (0.125e16 mg/kg, i.v.) was
administered.Fig. 2. The effect of ﬂuoxetine and reboxetine on neurons in the dorsal raphe nucleus of
16 mg/kg, i.v.) (A) and reboxetine (0.625e60 mg/kg, i.v) (B) on serotonergic neurons in the
correspondent antidepressant. The symbols represent the means  S.E.M. of the percentage
the reboxetine control, the reboxetine L-DOPA, the ﬂuoxetine control and the ﬂuoxetine L-DAdministering ﬂuoxetine alone signiﬁcantly decreased the
spontaneous ﬁring activity of neurons in the DRN in a dose-
dependant manner, as reported previously (Czachura and
Rasmussen, 2000; Miguelez et al., 2011b). When the administra-
tion of ﬂuoxetine was preceded by L-DOPA, ﬂuoxetine produced
an identical dose-dependant inhibitory effect (F(6,32) ¼ 50.66,
p < 0.0001, one-way ANOVA), and the doseeresponse curve of
ﬂuoxetine remained the same (Table 1 and Fig. 2A). ED50 values
were also similar between the two conditions (1.24  0.23 mg/kg,
n ¼ 8 for the control vs. 0.92  0.13 mg/kg, n ¼ 5 for the L-DOPA-
pretreated group, unpaired Student’s t-test, p > 0.05).
In agreement with earlier studies (Linner et al., 2004; Miguelez
et al., 2011b; Wong et al., 2000) reboxetine signiﬁcantly decreased
the spontaneous ﬁring activity of neurons in the DRN in a dose-
dependant manner. When reboxetine treatment was preceded by
the administration of L-DOPA, reboxetine produced a similar dose-
dependant inhibitory effect on these neurons (F(7,41) ¼ 20.19,
p < 0.0001, one-way ANOVA). Pre-treatment with L-DOPA did not
alter either the doseeresponse curves (Table 1 and Fig. 2B) or
the ED50 values (10.26  0.88 mg/kg, n ¼ 5 for the control vs.
10.41  1.93 mg/kg, n ¼ 8 for the L-DOPA-pretreated group,
unpaired Student’s t-test, p > 0.05) of reboxetine.
Thus, administration of L-DOPA together with reboxetine or
ﬂuoxetine did not modify the effect of each antidepressant on DRN
neuron activity.
3.4. Antidepressant-like effects of reboxetine and ﬂuoxetine
To determine the range of effective doses, the antidepressant-
like effects of reboxetine (2.8, 5.6 and 11.2 mg/kg, i.p.) and ﬂuoxe-
tine (5, 10 and 20 mg/kg, i.p.) were ﬁrst studied under control
conditions in the mFST.
As in Page et al. (2003), reboxetine reduced the immobility
time (F(3,31) ¼ 3.91, p < 0.05, one-way ANOVA) of the rats incontrol and L-DOPA-pretreated rats. The doseeresponse curves for ﬂuoxetine (0.125e
DRN of control and L-DOPA-injected rats. L-DOPA was administered 5 min before the
of reduction from the basal ﬁring rate, and n ¼ 5, 8, 11 and 7 animals were included in
OPA groups, respectively.
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in their climbing time (F(3,31) ¼ 3.27, p < 0.05, one-way ANOVA)
(Fig. 3A). In both cases, the values differed signiﬁcantly from
controls when 11.2 mg/kg of the drug was given (Dunnett post hoc
test). The rats’ swimming time was similar for all doses tested
(F(3,31) ¼ 0.45, p > 0.05, one-way ANOVA).
As shown in other studies (Detke et al., 1995, 1997) ﬂuoxetine
decreased the immobility time (F(3,23) ¼ 3.45, p < 0.05, one-way
ANOVA) and increased the swimming time (F(3,23) ¼ 3.51,
p< 0.05, one-way ANOVA) in a dose-dependant manner (Fig. 3B). A
post hoc Dunnett test revealed signiﬁcant differences when the
drugs were administered at 20 mg/kg compared with control
values. The climbing time was similar for all groups (F(3,23) ¼ 0.01,
p > 0.05, one-way ANOVA).
3.5. The effect of L-DOPA on the antidepressant-like effects of
reboxetine and ﬂuoxetine as assessed by the modiﬁed forced
swimming test
The effects of administering L-DOPA (6 mg/kg þ 15 mg/kg
benserazide, i.p.) in combination with reboxetine or ﬂuoxetine
were studied in rats that underwent the mFST. Based on the elec-
trophysiological results, ineffective doses of reboxetine (0.7, 1.4 and
2.8 mg/kg, i.p.) and an effective dose of ﬂuoxetine (20 mg/kg, i.p.)
were used in order to study if reboxetine rendered effective and
ﬂuoxetine had a weaker effect when they were co-administered
with L-DOPA.
A two-way ANOVA revealed that treatment with both rebox-
etine and L-DOPA had a signiﬁcant effect on both immobility and
climbing time. Furthermore, reboxetine also signiﬁcantly affectedFig. 3. The effect of reboxetine and ﬂuoxetine on the rats’ performance in the modiﬁed
forced swimming test. (A) The administration of reboxetine (11.2 mg/kg, i.p.) decreased
immobility and increased climbing behaviour compared with saline-treated animals.
Lower doses (2.8 and 5.6 mg/kg, i.p.) lacked any signiﬁcant effect. (B) The adminis-
tration of ﬂuoxetine (20 mg/kg, i.p.) also decreased immobility and increased swim-
ming behaviour compared with saline-treated animals. Lower doses (5 and 10 mg/kg,
i.p.) did not have a signiﬁcant effect. Im: immobility; sw: swimming behaviours; and
cl: climbing behaviours. The data are presented as the means  S.E.M. of the mean
counts, and 6e9 rats were included in each group. *: p < 0.05 when compared to the
saline-treated group (one-way ANOVA followed by a Dunnett post hoc test).the time the rats spent swimming (Table 1 and Fig. 4). Subse-
quently, a one-way ANOVA showed that L-DOPA treatment (1.4 and
2.8 mg/kg) increased the antidepressant-like effects of reboxetine
when compared with reboxetine alone. Thus, the administration of
L-DOPA along with 1.4 mg/kg of reboxetine decreased the immo-
bility of the rats (F(2,30) ¼ 4.59, p < 0.05) but did not modify their
swimming (F(2,30) ¼ 0.59, p > 0.05) or climbing time (F(2,30) ¼ 2.47,
p > 0.05). When a 2.8 mg/kg dose of reboxetine was given, L-DOPA
caused a reduction in the immobility (F(2,30) ¼ 3.44, p < 0.05) and
swimming (F(2,30) ¼ 6.45, p < 0.01) time but signiﬁcantly increased
the climbing time (F(2,30) ¼ 7.24, p< 0.01) during the mFST. None of
these behaviours were modiﬁed by L-DOPA that was combined
with a 0.7 mg/kg dose of reboxetine. A subsequent post hocDunnett
test showed signiﬁcant changes in mFST behaviours occurred
when a 1.4 or 2.8 mg/kg dose of reboxetine was combined with
a 12 mg/kg dose of L-DOPA (Fig. 4A, B and C).
When ﬂuoxetine and L-DOPA treatments were combined, a two-
way ANOVA revealed that both factors signiﬁcantly interacted to
affect immobility in the mFST, while the swimming and climbing
times were signiﬁcantly modiﬁed by ﬂuoxetine alone (Table 1 and
Fig. 5). Next, one-way ANOVA showed that L-DOPA reduced the
antidepressant-like effect of ﬂuoxetine at 20 mg/kg compared with
the administration of ﬂuoxetine alone. The administration of
L-DOPA increased the immobility at 20 mg/kg (F(2,25) ¼ 6.02,
p < 0.01) but did not modify swimming (F(2,25) ¼ 1.28, p > 0.05) or
climbing time (F(2,25) ¼ 0.07, p > 0.05). A post hoc Dunnett test
revealed signiﬁcant changes in mFST behaviours when 20 mg/kg of
ﬂuoxetine combined with 6 mg/kg of L-DOPA (Fig. 5A, B and C).
3.6. Evaluation of locomotor activity
To avoid the possibility that an enhancement of generalised
motor activity could explain the changes seen in mFST-related
behaviours, each antidepressant was administered alone and in
combination with L-DOPA to assess its ability to alter locomotor
activity in the locomotor activity chamber (Table 2).
A two-way ANOVA revealed that both L-DOPA and reboxetine
signiﬁcantly affected locomotor activity (Tables 1 and 2). A subse-
quent one-way ANOVA showed that the reboxetine-treated
animals had signiﬁcantly reduced locomotor activity compared
with the saline-treated animals (F(3,33) ¼ 6.52, p < 0.01) at all doses
of reboxetine. Administering L-DOPA further reduced the locomotor
activity when it was given in combination with reboxetine
(F(2,23)¼ 16.43, p< 0.001 for 0.7mg/kg of reboxetine; F(2,26)¼ 14.31,
p < 0.001 for 1.4 mg/kg of reboxetine and F(2,25) ¼ 6.22, p < 0.01 for
2.8 mg/kg reboxetine).
A two-way ANOVA also revealed that ﬂuoxetine signiﬁcantly
affected locomotor activity (Table 1). Indeed, 20 mg/kg of ﬂuoxe-
tine, which is a dose that has already been effective in the mFST,
also decreased the locomotor activity in a statistically signiﬁcant
manner when compared with the saline-treated animals (unpaired
Student’s t-test, p< 0.001, Table 2). However, administering L-DOPA
in combination did not modify the effect of ﬂuoxetine alone
(F(2,27) ¼ 0.64, p > 0.05).
This experiment demonstrated that the L-DOPA-induced effects
seen in the mFST are not due to the putative locomotor effect of the
drug. In combination with the antidepressants, L-DOPA enhanced
the hypoactivity that was induced by the antidepressants alone
rather than increasing hyperkinesia, which could mask the
antidepressant-like effect observed in the mFST.
4. Discussion
This study demonstrates that the co-administration of L-DOPA
along with an SSRI or an NRI can oppositely modify the effect of the
Fig. 4. The inﬂuence of L-DOPA pre-treatment on the antidepressant-like effects of reboxetine in the modiﬁed forced swimming test. The effects of L-DOPA (6 and
12 mg/kg þ 15 mg/kg of benserazide) and reboxetine (0.7, 1.4 and 2.8 mg/kg) on the immobility (A), swimming (B) and climbing behaviour (C) of rats undergoing the modiﬁed
forced swimming test were studied when the drugs were either given alone or in combination. The data are presented as the means  S.E.M. of the mean counts, and 9e11 rats were
included in each group. *: p < 0.05 and **: p < 0.01 when compared with the corresponding reboxetine-alone treatment group (Dunnett post hoc test).
Fig. 5. The inﬂuence of L-DOPA pre-treatment on the antidepressant-like effects of ﬂuoxetine in the modiﬁed forced swimming test. The effects of L-DOPA (6 and 12 mg/kg,
i.p. þ 15 mg/kg of benserazide) and ﬂuoxetine (20 mg/kg, i.p.) on the immobility (A), swimming (B) or climbing behaviour (C) of rats undergoing the modiﬁed forced swimming test
were studied when the drugs were either given alone or in combination. The data are presented as the means  S.E.M. of the mean counts, and 9e10 rats were included in each
group. **: p < 0.01 when compared with the corresponding ﬂuoxetine-alone treatment group (one-way ANOVA followed by Dunnett post hoc test); ###: p < 0.001 when compared
with the saline-treated group (unpaired Student’s t-test).
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Table 2
The effect of the co-administration of both antidepressants and L-DOPA on the spontaneous locomotor activity. L6 and L12 designate speciﬁc doses of L-DOPA (L6: 6 mg/kg of
L-DOPAþ 15mg/kg of benserazide, L12: 12mg/kg of L-DOPAþ 15mg/kg benserazide). The data are expressed as means S.E.M. of (n) animals during the 5-min testing period.
#: p< 0.05 and ###: p< 0.001 when compared with saline treatment (one-way ANOVA followed by a Dunnett post hoc test for reboxetine and an unpaired Student’s t-test for
ﬂuoxetine) *: p < 0.05, **: p < 0.01 and ***: p < 0.001 when compared with the corresponding reboxetine-alone treatment group (one-way ANOVA followed by Dunnett post
hoc test).
Treatment Dose(mg/kg), i.p. Treatment alone Treatment þ L6 Treatment þ L12
Vehicle(NaCl) 734.5  31.5 (10) 658.4  37.2 (10) 614.8  43.4 (10)
Reboxetine 0.7 663.4  11.7 (8) 547.9  10.8 (9)*** 529.6  25.1 (9)***
1.4 619.3  23.3 (10)## 531.0  25.9 (10)* 413.3  32 (9)***
2.8 589.0  26.2 (9)## 483.8  13.9 (9)* 413.3  32.1(9)***
Fluoxetine 20 218.1  28.9 (10)### 185.4  23.2 (9) 180.7  24.3 (9)
C. Miguelez et al. / Neuropharmacology 67 (2013) 349e358 355antidepressants. The electrophysiological data described here
indicate that L-DOPA augments the effect of reboxetine and atten-
uates the effect of ﬂuoxetine in the LC. Consistent with these
electrophysiological ﬁndings, pre-treatment with L-DOPA caused
non-effective doses of reboxetine to become effective, while
attenuating an effective dose of ﬂuoxetine as determined by the
mFST.
4.1. Signiﬁcance of the electrophysiological ﬁndings
We have previously demonstrated that chronic dopaminergic
denervation reduces the basal ﬁring activity of neurons in the LC
without changing the electrophysiological properties of neurons in
the DRN (Miguelez et al., 2011b). Interestingly, chronic treatment
with L-DOPA has been found to reverse these changes (Miguelez
et al., 2011a), which suggests that dopamine depletion or dopa-
minergic agents can importantly modulate the activity of neurons
in the LC. Here, we extend these results by demonstrating that
acute administration of 6 mg/kg of L-DOPA does not produce any
change in neuronal activity in the LC or the DRN of control animals.
This was an unexpected ﬁnding because neurons in both the LC and
the DRN express dopaminergic receptors (Bouthenet et al., 1987;
Mansour et al., 1990, 2003; Suzuki et al., 1998; Yokoyama et al.,
1994), and dopamine and dopaminergic drugs have been shown
to regulate their cellular activity (Guiard et al., 2008; Lin et al.,
2008; Martin-Ruiz et al., 2001). In addition, L-DOPA can be also
transformed into noradrenaline (Mercuri and Bernardi, 2005)
which can alter neuronal activity in the LC and DRN through a1 or
a2 adrenoceptors (Baraban and Aghajanian, 1980a, 1980b;
Cedarbaum and Aghajanian, 1976; Clement et al., 1992; Garratt
et al., 1991; Pudovkina and Westerink, 2005; Svensson et al.,
1975). The lack of effect of L-DOPA on LC and DRN basal activity
may rely on the necessity to apply higher doses of the drug.
Despite not modifying the basal parameters, the used dose of
L-DOPA was able to potentiate the effect of reboxetine or diminish
the effect of ﬂuoxetine in the LC, likely through different mecha-
nisms. Probably because exogenously administrated L-DOPA gives
rise to noradrenaline in the LC, concomitant administration of
L-DOPA and reboxetine signiﬁcantly enhanced the inhibitory
response to the antidepressant in the LC. In fact, exogenously
administered L-DOPA is immediately decarboxylated to dopamine,
which is then further transformed into noradrenaline in neurons
that contain dopamine-b-hydroxylase. This noradrenaline might
not have been sufﬁcient to induce an effect per sé, but in combi-
nation with reboxetine the antidepressant effect was augmented.
Reboxetine blocks noradrenaline transporters and inhibits the
ﬁring rate of neurons in the LC by increasing the concentration of
noradrenaline. Because L-DOPA and reboxetine were administered
together, the additive increase in noradrenaline in the LC likely
caused a quicker inhibition of the neuron activity. In support of this
idea, previous work from our group demonstrated that a low dose
of reboxetine potentiates the inhibitory effect of noradrenaline inthe LC (Grandoso et al., 2004). Supportive studies have reported
that the co-administration of noradrenaline with desipramine
enhances the effect of noradrenaline both in vitro and in vivo (Curet
et al., 1992; Williams et al., 1985). Additionally, L-DOPA binds
a2-adrenoceptors present in the LC (Alachkar et al., 2010), what
could explain, at least in part, the potentiated effect obtained when
L-DOPA and reboxetine are administered together.
In contrast, L-DOPA attenuated the effect of ﬂuoxetine on LC
cells. Previously, we have demonstrated that the effect of ﬂuoxetine
on LC cells is mediated by noradrenaline and a2 adrenoceptors and
that projecting neurons must be involved in this effect as it is
absent in brain slices (Miguelez et al., 2009). Because serotonergic
projecting neurons may intervene in this mechanism, adminis-
tering L-DOPA should attenuate the effects of ﬂuoxetine acting at
serotonergic terminal level. In fact, several evidences suggest that
endogenous serotonin is replaced by L-DOPA derived dopamine,
which can act as false neurotransmitter and diminish the effect of
serotonin. In this sense, serotonin levels decrease after L-DOPA
injection (Bartholini et al., 1968; Commissiong and Sedgwick, 1979;
Everett and Borcherding, 1970; Navailles et al., 2010a) and chronic
administration of oral L-DOPA reduces serotonin levels (Borah and
Mohanakumar, 2007) and excretions (Garcia et al., 1999). In
support of this, it is now well known that serotonergic neurons are
responsible for the ectopic release of dopamine induced by L-DOPA
being able to transform, store and release L-DOPA derived dopa-
mine (Navailles et al., 2010b). The presence of aromatic amino-acid
decarboxylase and the vesicular monoamine transporter 2 in
serotonergic neurons makes it feasible (Michelsen et al., 2007). This
fact has been proved both in parkinsonian animals (Carta et al.,
2007; Navailles et al., 2010a; Tanaka et al., 1999; Yamada et al.,
2007) and intact rats (Arai et al., 1994, 1995, 1996a, 1996b). Co-
administration of L-DOPA and ﬂuoxetine can therefore lead to
competition for the mechanisms involved in clearing or storing
dopamine and serotonin. Another explanation for the observed
interaction between the two drugs is that L-DOPA and ﬂuoxetine
have opposite effects on the same receptors. While both ﬂuoxetine
and dopamine bind 5-HT2C serotonin receptors, the former acts as
an antagonist (Koch et al., 2002; Millan et al., 1998; Palvimaki et al.,
1996), and the latter as an agonist (Oz et al., 2003; Woodward et al.,
1992), which could cause the effect of the antidepressant to be
attenuated by L-DOPA.
In the DRN, co-administration of L-DOPA with reboxetine or
ﬂuoxetine did not modify the inhibitory effect of both drugs on the
serotonergic cells. The DRN receives a dense dopaminergic inner-
vation from midbrain dopaminergic neurons (Kitahama et al.,
2000; Peyron et al., 1998) and also contains high levels of D2-like
and low levels of D1-like dopaminergic receptors (Bouthenet
et al., 1987; Mansour et al., 1990; Suzuki et al., 1998), dopamine
(Ferre et al., 1994) and dopaminergic neurons (Miachon et al., 1984;
Trulson et al., 1985; Yoshida et al., 1989). Overall, it is still unclear
whether dopamine or dopaminergic agents affect the DRN.
However, the results of this study support our previous study
C. Miguelez et al. / Neuropharmacology 67 (2013) 349e358356where the neuronal response to ﬂuoxetine was unaltered in the
DRN after nigro-striatal degeneration (Miguelez et al., 2011b). As
commented above, the difference between the inﬂuence of L-DOPA
on the LC and DRN may rely on the conversion of L-DOPA derived
dopamine into noradrenaline. In fact, the LC is a rich area in
dopamine-b-hydroxylase, while in the DRN this enzyme is lesser
expressed and it has been described only in the vicinity of the
nucleus (Baldo et al., 2003).
4.2. Behavioural impact of concomitant administration of L-DOPA
and antidepressants
The ﬁnding that the administration of reboxetine decreased
immobility and increased climbing behaviour in the mFST corrob-
orates previous studies (Connor et al., 1999; Harkin et al., 1999;
Page et al., 2003) which postulate that this antidepressant behav-
iour results from the increase in noradrenaline levels in the frontal
cortex (Page et al., 2003; Page and Lucki, 2002). The interaction of
the noradrenergic and dopaminergic systems has been widely
demonstrated (El Mansari et al., 2010). Previous studies have
indicated that reboxetine increases both noradrenaline and dopa-
mine levels in the frontal cortex (Dekeyne et al., 2001; Kitaichi et al.,
2004; Page and Lucki, 2002; Sacchetti et al., 1999). Similarly, L-
DOPA can increase both dopamine (Eltayb et al., 2005; Loefﬂer
et al., 1998) and noradrenaline levels in the cortex (Constantinidis
et al., 1968). Dopamine can be co-released with noradrenaline
from noradrenergic nerve terminals (Devoto et al., 2001, 2004,
2005), and noradrenaline transporters can also transport dopa-
mine (Horn,1973; Raiteri et al., 1977). In the cortex, L-DOPA-derived
dopamine can compete with noradrenaline for reuptake sites, and
noradrenaline levels can remain increased longer before the neuro-
transmitter is metabolised. This interaction between dopamine
and noradrenaline might underlie the potentiated antidepressant-
like effect observed when reboxetine and L-DOPA were co-
administered. Another possibility is that the L-DOPA-derived
dopaminewas converted into noradrenaline in the prefrontal cortex,
which is supported by the observation that local administration of
dopamine into the prefrontal cortex can increase extracellular
noradrenaline concentrations (Pan et al., 2004). The cortical release
of noradrenaline produced from L-DOPAwould potentiate the effects
of reboxetine and cause non-effective doses of the antidepressant to
become effective.
The ﬁnding that the sub-acute administration of ﬂuoxetine
produced a decrease in immobility and an increase in the swimming
behaviour in themFST is supported by previous studies (Detke et al.,
1995; Page et al., 1999). The mechanism underlying these behav-
ioural changes likely involves changes in the extracellular levels of
serotonin in the lateral septum (Kirby and Lucki, 1997). Moreover, it
seems unlikely that the blockade of the antidepressant effect of
ﬂuoxetine is the solely result of the competition between
a predominant behaviour because climbing is not increased in
expense of swimming. As extensively described above, several
ﬁndings have characterised interactions between the serotonin and
dopamine systems that may explain why the antidepressant effect
of ﬂuoxetine is blocked when the drug is co-administered with
L-DOPA. This effect was revealed with 6 but not 12 mg/kg of L-DOPA.
The raisonwhy this blockagewas observed at lower doses of L-DOPA
require further investigation andmay involve differentmechanisms.
In this line, a recent publication has reported that 20 mg/kg of
ﬂuoxetine administered together with 6 mg/kg of L-DOPA to
parkinsonian animals attenuates L-DOPA’s beneﬁcial effects on
motor performance while lower doses of the antidepressant with
the same dosage of L-DOPA improved it (Bishop et al., 2012).
Interaction between serotonergic and catecholaminergic
systems is supported by the analysis of immobility and activebehaviours. Immobility score, the classical parameter used, showed
that reboxetine-L-DOPA combination reduced it but the contrary
effect was seen for ﬂuoxetine-L-DOPA. The analysis of the predom-
inant active behaviours may inform about the underlying mecha-
nisms. In the case of reboxetine-L-DOPA this might be a summation
of the catecholaminergic activity because climbing behaviour is
increased, accordingly with the electrophysiological data.5. Conclusion
In conclusion, we have used both electrophysiological and
behavioural studies to demonstrate that L-DOPA potentiates the
effect of reboxetine but attenuates the effect of ﬂuoxetine. Two
main conclusions can be extracted from this work. On the one hand,
adding L-DOPA to the pharmacological treatment with NRI can be
a useful augmentation strategy for those patients that fail to
respond properly to the medication. On the other hand, the
concomitant use of L-DOPA with SSRI may deteriorate the thera-
peutic effect of the antidepressant. L-DOPA can therefore be useful
for augmenting the response to NRI but this beneﬁcial effect cannot
be applied to SSRI. This work provides new knowledge on the
interaction between antidepressants and L-DOPA, which may
contribute in developing clinical augmentation therapies for treat-
ment of drug-resistant depression.Acknowledgements
This study was supported by GIC IT-436-10, SAF 2009-08664,
FP7-PEOPLE-2010-RG-268377 and PI10/01221. Authors declare to
have no conﬂict of interests. CM has a fellowship from the Basque
Government. We thank Maria Torrecilla and Jan Tonnesen for their
critical comments about the manuscript.References
Alachkar, A., Brotchie, J.M., Jones, O.T., 2010. Binding of dopamine and
3-methoxytyramine as l-DOPA metabolites to human alpha(2)-adrenergic and
dopaminergic receptors. Neurosci. Res. 67, 245e249.
Alba-Delgado, C., Llorca-Torralba, M., Horrillo, I., Ortega, J.E., Mico, J.A., Sanchez-
Blazquez, P., Meana, J.J., Berrocoso, E., 2013. Chronic pain leads to concomitant
noradrenergic impairment and mood disorders. Biol. Psychiatr. 73, 54e62.
Arai, R., Karasawa, N., Geffard, M., Nagatsu, T., Nagatsu, I., 1994. Immunohisto-
chemical evidence that central serotonin neurons produce dopamine from
exogenous L-DOPA in the rat, with reference to the involvement of aromatic
L-amino acid decarboxylase. Brain Res. 667, 295e299.
Arai, R., Karasawa, N., Geffard, M., Nagatsu, I., 1995. L-DOPA is converted to dopa-
mine in serotonergic ﬁbers of the striatum of the rat: a double-labeling
immunoﬂuorescence study. Neurosci. Lett. 195, 195e198.
Arai, R., Karasawa, N., Nagatsu, I., 1996a. Aromatic L-amino acid decarboxylase is
present in serotonergic ﬁbers of the striatum of the rat. A double-labeling
immunoﬂuorescence study. Brain Res. 706, 177e179.
Arai, R., Karasawa, N., Nagatsu, I., 1996b. Dopamine produced from L-DOPA is
degraded by endogenous monoamine oxidase in neurons of the dorsal raphe
nucleus of the rat: an immunohistochemical study. Brain Res. 722, 181e184.
Baldo, B.A., Daniel, R.A., Berridge, C.W., Kelley, A.E., 2003. Overlapping distributions
of orexin/hypocretin- and dopamine-beta-hydroxylase immunoreactive ﬁbers
in rat brain regions mediating arousal, motivation, and stress. J. Comp. Neurol.
464, 220e237.
Baraban, J.M., Aghajanian, G.K., 1980a. Suppression of ﬁring activity of 5-HT neurons
in the dorsal raphe by alpha-adrenoceptor antagonists. Neuropharmacology 19,
355e363.
Baraban, J.M., Aghajanian, G.K., 1980b. Suppression of serotonergic neuronal ﬁring
by alpha-adrenoceptor antagonists: evidence against GABA mediation. Eur. J.
Pharmacol. 66, 287e294.
Bartholini, G., Da Prada, M., Pletscher, A., 1968. Decrease of cerebral 5-
hydroxytryptamine by 3,4-dihydroxyphenylalanine after inhibition of extrac-
erebral decarboxylase. J. Pharm. Pharmacol. 20, 228e229.
Bauer, M., Adli, M., Bschor, T., Pilhatsch, M., Pfennig, A., Sasse, J., Schmid, R.,
Lewitzka, U., 2010. Lithium’s emerging role in the treatment of refractory major
depressive episodes: augmentation of antidepressants. Neuropsychobiology 62,
36e42.
Bishop, C., George, J.A., Buchta, W., Goldenberg, A.A., Mohamed, M., Dickinson, S.O.,
Eissa, S., Eskow Jaunarajs, K.L., 2012. Serotonin transporter inhibition attenuates
C. Miguelez et al. / Neuropharmacology 67 (2013) 349e358 357l-DOPA-induced dyskinesia without compromising l-DOPA efﬁcacy in hemi-
parkinsonian rats. Eur. J. Neurosci. 36, 2839e2848.
Blier, P., 2008. Resiliency of monoaminergic systems: the 80% rule and its relevance
to drug development. J. Psychopharmacol. 22, 587e589.
Borah, A., Mohanakumar, K.P., 2007. Long-term L-DOPA treatment causes indis-
criminate increase in dopamine levels at the cost of serotonin synthesis in
discrete brain regions of rats. Cell. Mol. Neurobiol. 27, 985e996.
Bouthenet, M.L., Martres, M.P., Sales, N., Schwartz, J.C., 1987. A detailed mapping of
dopamine D-2 receptors in rat central nervous system by autoradiography with
[125I]iodosulpride. Neuroscience 20, 117e155.
Bravo, L., Mico, J.A., Rey-Brea, R., Perez-Nievas, B., Leza, J.C., Berrocoso, E., 2012.
Depressive-like states heighten the aversion to painful stimuli in a rat model of
comorbid chronic pain and depression. Anesthesiology 117, 613e625.
Carta, M., Carlsson, T., Kirik, D., Bjorklund, A., 2007. Dopamine released from 5-HT
terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain
130, 1819e1833.
Cassano, P., Lattanzi, L., Soldani, F., Navari, S., Battistini, G., Gemignani, A.,
Cassano, G.B., 2004. Pramipexole in treatment-resistant depression: an
extended follow-up. Depress Anxiety 20, 131e138.
Cassano, P., Lattanzi, L., Fava, M., Navari, S., Battistini, G., Abelli, M., Cassano, G.B.,
2005. Ropinirole in treatment-resistant depression: a 16-week pilot study. Can.
J. Psychiatr. 50, 357e360.
Cedarbaum, J.M., Aghajanian, G.K., 1976. Noradrenergic neurons of the locus
coeruleus: inhibition by epinephrine and activation by the alpha-antagonist
piperoxane. Brain Res. 112, 413e419.
Clement, H.W., Gemsa, D., Wesemann, W., 1992. Serotonin-norepinephrine inter-
actions: a voltammetric study on the effect of serotonin receptor stimulation
followed in the N. raphe dorsalis and the Locus coeruleus of the rat. J. Neural
Transm. Gen. Sect. 88, 11e23.
Commissiong, J.W., Sedgwick, E.M., 1979. Depletion of 5-HT by L-DOPA in spinal
cord and brainstem of rat. Life Sci. 25, 83e86.
Connor, T.J., Kelliher, P., Harkin, A., Kelly, J.P., Leonard, B.E., 1999. Reboxetine
attenuates forced swim test-induced behavioural and neurochemical alter-
ations in the rat. Eur. J. Pharmacol. 379, 125e133.
Constantinidis, J., Bartholini, G., Tissot, R., Pletscher, A., 1968. Accumulation of
dopamine in the parenchyma after decarboxylase inhibition in the capillaries of
brain. Experientia 24, 130e131.
Cryan, J.F., Valentino, R.J., Lucki, I., 2005. Assessing substrates underlying the
behavioral effects of antidepressants using the modiﬁed rat forced swimming
test. Neurosci. Biobehav. Rev. 29, 547e569.
Curet, O., De Montigny, C., Blier, P., 1992. Effect of desipramine and amphetamine on
noradrenergic neurotransmission: electrophysiological studies in the rat brain.
Eur. J. Pharmacol. 221, 59e70.
Czachura, J.F., Rasmussen, K., 2000. Effects of acute and chronic administration of
ﬂuoxetine on the activity of serotonergic neurons in the dorsal raphe nucleus of
the rat. Naunyn Schmiedebergs Arch. Pharmacol. 362, 266e275.
Dawe, G.S., Huff, K.D., Vandergriff, J.L., Sharp, T., O’Neill, M.J., Rasmussen, K., 2001.
Olanzapine activates the rat locus coeruleus: in vivo electrophysiology and
c-Fos immunoreactivity. Biol. Psychiatr. 50, 510e520.
Dekeyne, A., Gobert, A., Iob, L., Cistarelli, L., Melon, C., Millan, M.J., 2001. Discrimi-
native stimulus properties of the selective norepinephrine reuptake inhibitor,
reboxetine, in rats. Psychopharmacology (Berl). 158, 213e218.
Detke, M.J., Rickels, M., Lucki, I., 1995. Active behaviors in the rat forced swimming
test differentially produced by serotonergic and noradrenergic antidepressants.
Psychopharmacology (Berl). 121, 66e72.
Detke, M.J., Johnson, J., Lucki, I., 1997. Acute and chronic antidepressant drug
treatment in the rat forced swimming test model of depression. Exp. Clin.
Psychopharmacol. 5, 107e112.
Devoto, P., Flore, G., Pani, L., Gessa, G.L., 2001. Evidence for co-release of
noradrenaline and dopamine from noradrenergic neurons in the cerebral
cortex. Mol. Psychiatr. 6, 657e664.
Devoto, P., Flore, G., Pira, L., Longu, G., Gessa, G.L., 2004. Alpha2-adrenoceptor
mediated co-release of dopamine and noradrenaline from noradrenergic
neurons in the cerebral cortex. J. Neurochem. 88, 1003e1009.
Devoto, P., Flore, G., Saba, P., Fa, M., Gessa, G.L., 2005. Co-release of noradrenaline
and dopamine in the cerebral cortex elicited by single train and repeated train
stimulation of the locus coeruleus. BMC Neurosci. 6, 31.
Dhillon, S., Yang, L.P., Curran, M.P., 2008. Bupropion: a review of its use in the
management of major depressive disorder. Drugs 68, 653e689.
El Mansari, M., Guiard, B.P., Chernoloz, O., Ghanbari, R., Katz, N., Blier, P., 2010.
Relevance of norepinephrineedopamine interactions in the treatment of major
depressive disorder. CNS Neurosci. Ther. 16, e1e17.
Eltayb, A., Wadenberg, M.L., Svensson, T.H., 2005. Enhanced cortical dopamine
output and antipsychotic-like effect of raclopride with adjunctive low-dose
L-dopa. Biol. Psychiatr. 58, 337e343.
Engstrom, G., Alling, C., Blennow, K., Regnell, G., Traskman-Bendz, L., 1999. Reduced
cerebrospinal HVA concentrations and HVA/5-HIAA ratios in suicide attemp-
ters. Monoamine metabolites in 120 suicide attempters and 47 controls. Eur.
Neuropsychopharmacol. 9, 399e405.
Everett, G.M., Borcherding, J.W., 1970. L-DOPA: effect on concentrations of
dopamine, norepinephrine, and serotonin in brains of mice. Science 168,
847e850.
Ferre, S., Cortes, R., Artigas, F., 1994. Dopaminergic regulation of the serotonergic
raphe-striatal pathway: microdialysis studies in freely moving rats. J. Neurosci.
14, 4839e4846.Garcia, N.H., Berndt, T.J., Tyce, G.M., Knox, F.G., 1999. Chronic oral L-DOPA increases
dopamine and decreases serotonin excretions. Am. J. Physiol. 277, R1476e
R1480.
Garratt, J.C., Crespi, F., Mason, R., Marsden, C.A., 1991. Effects of idazoxan on dorsal
raphe 5-hydroxytryptamine neuronal function. Eur. J. Pharmacol. 193, 87e93.
Grandoso, L., Pineda, J., Ugedo, L., 2004. Comparative study of the effects of desi-
pramine and reboxetine on locus coeruleus neurons in rat brain slices.
Neuropharmacology 46, 815e823.
Guiard, B.P., El Mansari, M., Merali, Z., Blier, P., 2008. Functional interactions
between dopamine, serotonin and norepinephrine neurons: an in-vivo elec-
trophysiological study in rats with monoaminergic lesions. Int. J. Neuro-
psychopharmacol., 1e15.
Hamner, M.B., Diamond, B.I., 1996. Plasma dopamine and norepinephrine correla-
tions with psychomotor retardation, anxiety, and depression in non-psychotic
depressed patients: a pilot study. Psychiatr. Res. 64, 209e211.
Harkin, A., Kelly, J.P., McNamara, M., Connor, T.J., Dredge, K., Redmond, A.,
Leonard, B.E., 1999. Activity and onset of action of reboxetine and effect of
combination with sertraline in an animal model of depression. Eur. J. Phar-
macol. 364, 123e132.
Hemmerle, A.M., Herman, J.P., Seroogy, K.B., 2012. Stress, depression and Parkin-
son’s disease. Exp. Neurol. 233, 79e86.
Horn, A.S., 1973. Structureeactivity relations for the inhibition of catecholamine
uptake into synaptosomes from noradrenaline and dopaminergic neurones in
rat brain homogenates. Br. J. Pharmacol. 47, 332e338.
Inoue, T., Kitaichi, Y., Masui, T., Nakagawa, S., Boku, S., Tanaka, T., Suzuki, K.,
Nakato, Y., Usui, R., Koyama, T., 2010. Pramipexole for stage 2 treatment-
resistant major depression: an open study. Prog. Neuropsychopharmacol. Biol.
Psychiatr. 34, 1446e1449.
Kapur, S., Mann, J.J., 1992. Role of the dopaminergic system in depression. Biol.
Psychiatr. 32, 1e17.
Kessler, R.C., Merikangas, K.R., Wang, P.S., 2007. Prevalence, comorbidity, and
service utilization for mood disorders in the United States at the beginning of
the twenty-ﬁrst century. Annu. Rev. Clin. Psychol. 3, 137e158.
Kirby, L.G., Lucki, I., 1997. Interaction between the forced swimming test and
ﬂuoxetine treatment on extracellular 5-hydroxytryptamine and 5-
hydroxyindoleacetic acid in the rat. J. Pharmacol. Exp. Ther. 282, 967e976.
Kitahama, K., Nagatsu, I., Geffard, M., Maeda, T., 2000. Distribution of dopamine-
immunoreactive ﬁbers in the rat brainstem. J. Chem. Neuroanat. 18, 1e9.
Kitaichi, Y., Inoue, T., Nakagawa, S., Izumi, T., Koyama, T., 2004. Effect of co-
administration of lithium and reboxetine on extracellular monoamine
concentrations in rats. Eur. J. Pharmacol. 489, 187e191.
Klimek, V., Schenck, J.E., Han, H., Stockmeier, C.A., Ordway, G.A., 2002. Dopami-
nergic abnormalities in amygdaloid nuclei in major depression: a postmortem
study. Biol. Psychiatr. 52, 740e748.
Koch, S., Perry, K.W., Nelson, D.L., Conway, R.G., Threlkeld, P.G., Bymaster, F.P., 2002.
R-ﬂuoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal
cortex and hypothalamus: an in vivo microdialysis and receptor binding study.
Neuropsychopharmacology 27, 949e959.
Lambert, G., Johansson, M., Agren, H., Friberg, P., 2000. Reduced brain norepi-
nephrine and dopamine release in treatment-refractory depressive illness:
evidence in support of the catecholamine hypothesis of mood disorders. Arch.
Gen. Psychiatr. 57, 787e793.
Lieberman, A., 2006. Depression in Parkinson’s disease e a review. Acta Neurol.
Scand. 113, 1e8.
Lin, Y., Quartermain, D., Dunn, A.J., Weinshenker, D., Stone, E.A., 2008. Possible
dopaminergic stimulation of locus coeruleus alpha1-adrenoceptors involved in
behavioral activation. Synapse 62, 516e523.
Lindgren, H.S., Andersson, D.R., Lagerkvist, S., Nissbrandt, H., Cenci, M.A., 2010.
L-DOPA-induced dopamine efﬂux in the striatum and the substantia nigra in
a rat model of Parkinson’s disease: temporal and quantitative relationship to
the expression of dyskinesia. J. Neurochem. 112, 1465e1476.
Linner, L., Wiker, C., Arborelius, L., Schalling, M., Svensson, T.H., 2004. Selective
noradrenaline reuptake inhibition enhances serotonergic neuronal activity and
transmitter release in the rat forebrain. J. Neural Transm. 111, 127e139.
Loefﬂer, D.A., LeWitt, P.A., Juneau, P.L., Camp, D.M., Arnold, L.A., Hyland, K., 1998.
Time-dependent effects of levodopa on regional brain dopamine metabolism
and lipid peroxidation. Brain Res. Bull. 47, 663e667.
Mansour, A., Meador-Woodruff, J.H., Bunzow, J.R., Civelli, O., Akil, H., Watson, S.J.,
1990. Localization of dopamine D2 receptor mRNA and D1 and D2 receptor
binding in the rat brain and pituitary: an in situ hybridization-receptor auto-
radiographic analysis. J. Neurosci. 10, 2587e2600.
Mansour, A.A., Babstock, D.M., Penney, J.H., Martin, G.M., McLean, J.H., Harley, C.W.,
2003. Novel objects in a holeboard probe the role of the locus coeruleus in
curiosity: support for two modes of attention in the rat. Behav. Neurosci. 117,
621e631.
Martin-Ruiz, R., Ugedo, L., Honrubia, M.A., Mengod, G., Artigas, F., 2001. Control of
serotonergic neurons in rat brain by dopaminergic receptors outside the dorsal
raphe nucleus. J. Neurochem. 77, 762e775.
Mercuri, N.B., Bernardi, G., 2005. The ‘magic’ of L-dopa: why is it the gold standard
Parkinson’s disease therapy? Trends Pharmacol. Sci. 26, 341e344.
Meyer, J.H., Kruger, S., Wilson, A.A., Christensen, B.K., Goulding, V.S., Schaffer, A.,
Miniﬁe, C., Houle, S., Hussey, D., Kennedy, S.H., 2001. Lower dopamine transporter
binding potential in striatum during depression. Neuroreport 12, 4121e4125.
Miachon, S., Berod, A., Leger, L., Chat, M., Hartman, B., Pujol, J.F., 1984. Identiﬁcation
of catecholamine cell bodies in the pons and pons-mesencephalon junction of
C. Miguelez et al. / Neuropharmacology 67 (2013) 349e358358the cat brain, using tyrosine hydroxylase and dopamine-beta-hydroxylase
immunohistochemistry. Brain Res. 305, 369e374.
Michelsen, K.A., Schmitz, C., Steinbusch, H.W., 2007. The dorsal raphe nucleusefrom
silver stainings to a role in depression. Brain Res. Rev. 55, 329e342.
Miguelez, C., Fernandez-Aedo, I., Torrecilla, M., Grandoso, L., Ugedo, L., 2009.
Alpha(2)-adrenoceptors mediate the acute inhibitory effect of ﬂuoxetine on
locus coeruleus noradrenergic neurons. Neuropharmacology 56, 1068e1073.
Miguelez, C., Aristieta, A., Cenci, M.A., Ugedo, L., 2011a. The locus coeruleus is
directly implicated in L-DOPA-induced dyskinesia in parkinsonian rats: an
electrophysiological and behavioural study. PLoS One 6, e24679.
Miguelez, C., Grandoso, L., Ugedo, L., 2011b. Locus coeruleus and dorsal raphe
neuron activity and response to acute antidepressant administration in a rat
model of Parkinson’s disease. Int. J. Neuropsychopharmacol. 14, 187e200.
Millan, M.J., Dekeyne, A., Gobert, A., 1998. Serotonin (5-HT)2C receptors tonically
inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the
frontal cortex in vivo. Neuropharmacology 37, 953e955.
Navailles, S., Benazzouz, A., Bioulac, B., Gross, C., De Deurwaerdere, P., 2010a.
High-frequency stimulation of the subthalamic nucleus and L-3,4-
dihydroxyphenylalanine inhibit in vivo serotonin release in the prefrontal
cortex and hippocampus in a rat model of Parkinson’s disease. J. Neurosci. 30,
2356e2364.
Navailles, S., Bioulac, B., Gross, C., De Deurwaerdere, P., 2010b. Serotonergic neurons
mediate ectopic release of dopamine induced by L-DOPA in a rat model of
Parkinson’s disease. Neurobiol. Dis. 38, 136e143.
Oz, M., Zhang, L., Rotondo, A., Sun, H., Morales, M., 2003. Direct activation by
dopamine of recombinant human 5-HT1A receptors: comparison with human
5-HT2C and 5-HT3 receptors. Synapse 50, 303e313.
Page, M.E., Lucki, I., 2002. Effects of acute and chronic reboxetine treatment on stress-
induced monoamine efﬂux in the rat frontal cortex. Neuropsychopharmacology
27, 237e247.
Page, M.E., Detke, M.J., Dalvi, A., Kirby, L.G., Lucki, I., 1999. Serotonergic mediation of
the effects of ﬂuoxetine, but not desipramine, in the rat forced swimming test.
Psychopharmacology (Berl). 147, 162e167.
Page, M.E., Brown, K., Lucki, I., 2003. Simultaneous analyses of the neurochemical
and behavioral effects of the norepinephrine reuptake inhibitor reboxetine in
a rat model of antidepressant action. Psychopharmacology (Berl). 165, 194e201.
Palvimaki, E.P., Roth, B.L., Majasuo, H., Laakso, A., Kuoppamaki, M., Syvalahti, E.,
Hietala, J., 1996. Interactions of selective serotonin reuptake inhibitors with the
serotonin 5-HT2c receptor. Psychopharmacology (Berl). 126, 234e240.
Pan, W.H., Yang, S.Y., Lin, S.K., 2004. Neurochemical interaction between dopami-
nergic and noradrenergic neurons in the medial prefrontal cortex. Synapse 53,
44e52.
Papakostas, G.I., 2006. Dopaminergic-based pharmacotherapies for depression. Eur.
Neuropsychopharmacol. 16, 391e402.
Peyron, C., Petit, J.M., Rampon, C., Jouvet, M., Luppi, P.H., 1998. Forebrain afferents to
the rat dorsal raphe nucleus demonstrated by retrograde and anterograde
tracing methods. Neuroscience 82, 443e468.
Pudovkina, O.L., Westerink, B.H., 2005. Functional role of alpha1-adrenoceptors in
the locus coeruleus: a microdialysis study. Brain Res. 1061, 50e56.Raiteri, M., Del Carmine, R., Bertollini, A., Levi, G., 1977. Effect of sympathomimetic
amines on the synaptosomal transport of noradrenaline, dopamine and
5-hydroxytryptamine. Eur. J. Pharmacol. 41, 133e143.
Sacchetti, G., Bernini, M., Bianchetti, A., Parini, S., Invernizzi, R.W., Samanin, R., 1999.
Studies on the acute and chronic effects of reboxetine on extracellular
noradrenaline and other monoamines in the rat brain. Br. J. Pharmacol. 128,
1332e1338.
Schulte-Herbruggen, O., Vogt, M.A., Hortnagl, H., Gass, P., Hellweg, R., 2012.
Pramipexole is active in depression tests and modulates monoaminergic
transmission, but not brain levels of BDNF in mice. Eur. J. Pharmacol. 677,
77e86.
Suzuki, M., Hurd, Y.L., Sokoloff, P., Schwartz, J.C., Sedvall, G., 1998. D3 dopamine
receptor mRNA is widely expressed in the human brain. Brain Res. 779, 58e74.
Svensson, T.H., Bunney, B.S., Aghajanian, G.K., 1975. Inhibition of both noradrenergic
and serotonergic neurons in brain by the alpha-adrenergic agonist clonidine.
Brain Res. 92, 291e306.
Szabo, S.T., Blier, P., 2001. Effect of the selective noradrenergic reuptake inhibitor
reboxetine on the ﬁring activity of noradrenaline and serotonin neurons. Eur. J.
Neurosci. 13, 2077e2087.
Tanaka, H., Kannari, K., Maeda, T., Tomiyama, M., Suda, T., Matsunaga, M., 1999. Role
of serotonergic neurons in L-DOPA-derived extracellular dopamine in the
striatum of 6-OHDA-lesioned rats. Neuroreport 10, 631e634.
Trulson, M.E., Cannon, M.S., Raese, J.D., 1985. Identiﬁcation of dopamine-containing
cell bodies in the dorsal and median raphe nuclei of the rat brain using tyrosine
hydroxylase immunochemistry. Brain Res. Bull. 15, 229e234.
Vieta, E., Colom, F., 2011. Therapeutic options in treatment-resistant depression.
Ann. Med. 43, 512e530.
Williams, J.T., Henderson, G., North, R.A., 1985. Characterization of alpha 2-
adrenoceptors which increase potassium conductance in rat locus coeruleus
neurones. Neuroscience 14, 95e101.
Wong, E.H., Sonders, M.S., Amara, S.G., Tinholt, P.M., Piercey, M.F., Hoffmann, W.P.,
Hyslop, D.K., Franklin, S., Porsolt, R.D., Bonsignori, A., Carfagna, N.,
McArthur, R.A., 2000. Reboxetine: a pharmacologically potent, selective, and
speciﬁc norepinephrine reuptake inhibitor. Biol. Psychiatr. 47, 818e829.
Woodward, R.M., Panicker, M.M., Miledi, R., 1992. Actions of dopamine and dopa-
minergic drugs on cloned serotonin receptors expressed in Xenopus oocytes.
Proc. Natl. Acad. Sci. U. S. A. 89, 4708e4712.
Yamada, H., Aimi, Y., Nagatsu, I., Taki, K., Kudo, M., Arai, R., 2007. Immunohisto-
chemical detection of L-DOPA-derived dopamine within serotonergic ﬁbers in
the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
Neurosci. Res. 59, 1e7.
Yokoyama, C., Okamura, H., Nakajima, T., Taguchi, J., Ibata, Y., 1994. Autoradio-
graphic distribution of [3H]YM-09151-2, a high-afﬁnity and selective antagonist
ligand for the dopamine D2 receptor group, in the rat brain and spinal cord.
J. Comp. Neurol. 344, 121e136.
Yoshida, M., Shirouzu, M., Tanaka, M., Semba, K., Fibiger, H.C., 1989. Dopaminergic
neurons in the nucleus raphe dorsalis innervate the prefrontal cortex in the rat:
a combined retrograde tracing and immunohistochemical study using anti-
dopamine serum. Brain Res. 496, 373e376.
